ARTICLE | Product Development
Positive data from second Phase III trial of veligrotug in thyroid eye disease; this time in chronic setting
By Stephen Hansen, Director of Biopharma Intelligence
December 17, 2024 12:07 AM UTC
A second positive Phase III readout in just three months has Viridian’s veligrotug poised to challenge Amgen’s Tepezza in the thyroid eye disease market.
Viridian Therapeutics Inc. (NASDAQ:VRDN) announced Monday that the Phase III THRIVE-2 trial of veligrotug met the primary and secondary endpoints in the chronic thryoid eye disease (TED) setting. On the primary endpoint of proptosis responder rate (PRR), Viridian said 56% of patients treated with the anti-IGF1R mAb met the responder criteria vs. just 8% for placebo — a 48% placebo-adjusted PRR at week 15. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.biocentury.com/article/654497/viridian-taking-on-amgen-in-ted-market